That is an impressive resume.
This quote seems to have an aroma of confidence in SPL's science
Dr Jeff Davies said: “I am very excited to join Starpharma’s board, having followed and
admired the company for some years. Starpharma has an impressive commercial and
development pipeline based on its proprietary dendrimer platform, with multiple high-value
assets in the clinic and on market. I look forward to contributing to Starpharma’s future
success.”
Lets hope Jeff can get the job done
Ann: Dr Jeff Davies appointed as non-executive director, page-10
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 586785 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 56840 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |